A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.

Palak G PatelThomas WesselAtsunari KawashimaJohn B A OkelloTamara JamaspishviliKarl-Philippe GuérardLaura LeeAnna Ying-Wah LeeNathan E HowDan DionEleonora ScarlataChelsea L JacksonSuzanne BoursalieTanya SackRachel DunnMadeleine MoussaKaren Mackie/Audrey EllisElizabeth MarraJoseph ChinKhurram SiddiquiKhalil HetouLee-Anne PickardVinolia Arthur-HaywardGlenn BaumanSimone ChevalierFadi BrimoPaul C BoutrosJacques Lapointe PhDJohn M S BartlettRobert J GoodingDavid M Berman

Published in: The Prostate (2019)

We created and validated a multigene model for the classification of benign and malignant prostate tissue. With false positive and negative rates below 7%, this three-gene biomarker represents a promising basis for more accurate prostate cancer diagnosis.

Keyphrases

prostate cancer
genome wide
early stage
dna methylation
radical prostatectomy
copy number
machine learning
genome wide identification
gene expression
high resolution
squamous cell carcinoma
neoadjuvant chemotherapy